Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

TB transmission and prevention news

Show

From To
GSK candidate vaccine helps prevent active pulmonary tuberculosis in HIV negative adults in phase II study

Today, GSK and Aeras reported that GSK’s M72/AS01E[1] candidate vaccine significantly reduced the incidence of pulmonary tuberculosis disease in HIV-negative adults with latent tuberculosis infection[2] in an ongoing phase IIb clinical trial testing. These primary results published in the New England Journal of Medicine after two years of trial demonstrate an overall vaccine efficacy of 54%, with varied response rates observed in different demographic sub-groups.

Published
26 September 2018
From
Aeras
TB symptom screen less likely to detect active TB in people taking HIV treatment

The four-symptom screen for active tuberculosis (TB) that is recommended for all people living with HIV in lower-income settings is less likely to detect active TB in

Published
14 September 2018
By
Keith Alcorn
New TB cases occur rapidly among close contacts of people with pulmonary TB

The close contacts of people with active pulmonary tuberculosis (TB) have high rates of the disease, according to US and Canadian research published in The

Published
12 June 2018
By
Michael Carter
Hepatitis B or raised liver enzymes predict liver toxicity when TB prevention drug is combined with HIV treatment

The risk of liver toxicity in people with HIV taking antiretroviral therapy and isoniazid preventive therapy for tuberculosis is strongly associated with either hepatitis B

Published
06 June 2018
By
Michael Carter
TB Treatment May Leave Some Patients Contagious

The World Health Organization’s dosage guidelines for two leading tuberculosis medications may be far too low for patients with H.I.V., allowing them to remain contagious for longer than necessary, a new study has found.

Published
09 April 2018
From
New York Times
Isoniazid preventive therapy: do the risks outweigh the benefits in pregnant women with HIV?

Isoniazid preventive therapy (IPT) during and after pregnancy in women living with HIV on antiretroviral therapy (ART) in tuberculosis (TB) endemic areas in Africa, Asia

Published
13 March 2018
By
Carole Leach-Lemens
One-month TB prevention regimen just as effective as 9-month regimen

A one-month course of the antibiotic rifapentine combined with isoniazid was just as effective as a nine-month course of isoniazid in preventing the development of tuberculosis in people

Published
06 March 2018
By
Keith Alcorn
TB vaccine trial results offer potential for BCG Revaccination, hope for subunit vaccines

Aeras, a nonprofit organization dedicated to developing vaccines against tuberculosis (TB), today announced results from an innovative clinical trial that provides encouraging new evidence that TB vaccines could prevent sustained infections in high-risk adolescents. In a prevention-of-infection Phase 2 trial conducted in South Africa, revaccination with the Bacille Calmette-Guerin (BCG) vaccine significantly reduced sustained TB infections in adolescents. An experimental vaccine candidate, H4:IC31, also reduced sustained infections, although not at statistically significant levels.

Published
19 February 2018
From
Eurekalert Medicine & Health
Zambia: HIV deaths on treatment underestimated

People with HIV in Zambia were at least ten times more likely to die in the first two years after starting antiretroviral treatment than European

Published
14 February 2018
By
Keith Alcorn
The 2017 Pipeline Report

Treatment Action Group (TAG) announces the launch of its annual research and development landscape analysis: The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

Published
19 July 2017
From
Treatment Action Group

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.